[Immunotherapy of poor-prognosis neuroblastoma in children: from bench to bedside].
During the last two decades, improvements in the induction and consolidation treatment phases in patients with high-risk neuroblastoma have not translated into significant increases in survival rates. Efforts to improve outcome have used high-dose chemotherapy with stem cell rescue and more recently, differentiating (retinoids) and antiangiogenic agents. In parallel, immunotherapy has become an increasingly important part of the treatment of high-risk neuroblastoma. We review here the biological concepts underlying these new approaches and their clinical applications, with a particular emphasis on applications that manipulate the immune system, including monoclonal antibodies, gene-modified tumor cells (vaccines) or immune effectors.
Rousseau
Raphaël
R
Service de pédiatrie, Centre Léon Bérard, Lyon, France. roussea@lyon.fnclcc.fr
Combaret
Valérie
V
Yvon
Eric
E
Schell
Matthias
M
Philip
Irène
I
Puisieux
Alain
A
Frappaz
Didier
D
Philip
Thierry
T
Bergeron
Christophe
C
D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009447:Neuroblastoma / Q000276:immunology / Q000628:therapy*; D011379:Prognosis